Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness

To determine the prevalence of the HOXB13 G84E mutation (rs138213197) in Danish men with or without prostate cancer (PCa) and to investigate possible correlations between HOXB13 mutation status and clinicopathological characteristics associated with tumour aggressiveness.

[1]  I. Tannock,et al.  Prostate cancer , 2016, The Lancet.

[2]  Eva Steliarova-Foucher,et al.  Reprint of: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012 , 2015 .

[3]  K. D. Sørensen,et al.  Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[4]  R. Eeles,et al.  Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[6]  Peter Kraft,et al.  A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer , 2014, Nature Genetics.

[7]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[8]  K. Cooney,et al.  Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy , 2014, BJU international.

[9]  A. Chinnaiyan,et al.  HOXB13 G84E–related Familial Prostate Cancers: A Clinical, Histologic, and Molecular Survey , 2014, The American journal of surgical pathology.

[10]  B. Cai,et al.  G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis , 2014, Tumor Biology.

[11]  A. Kibel.  Association Between Germline HOXB13 G84E Mutation and Risk of Prostate Cancer , 2013 .

[12]  Søren Brunak,et al.  Whole-exome sequencing of 2,000 Danish individuals and the role of rare coding variants in type 2 diabetes. , 2013, American journal of human genetics.

[13]  C. Greenwood,et al.  The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. , 2013, Carcinogenesis.

[14]  J. Stanford,et al.  HOXB13 mutations in a population‐based, case–control study of prostate cancer , 2013, The Prostate.

[15]  A. Edwards,et al.  A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice—the ProCaRis study: study protocol , 2013, BMJ Open.

[16]  J. Mefford,et al.  HOXB13 Mutation and Prostate Cancer: Studies of Siblings and Aggressive Disease , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[17]  Suzanne Chambers,et al.  A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. , 2013, Human molecular genetics.

[18]  L. Aaltonen,et al.  HOXB13 G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[19]  Joan P. Breyer,et al.  Confirmation of the HOXB13 G84E Germline Mutation in Familial Prostate Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[20]  M. Borre,et al.  Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer , 2012 .

[21]  J. Carpten,et al.  Germline mutations in HOXB13 and prostate-cancer risk. , 2012, The New England journal of medicine.

[22]  Suzanne Chambers,et al.  Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study , 2011, Nature Genetics.

[23]  K. Iczkowski,et al.  Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome , 2011, Prostate cancer.

[24]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[25]  D. McDonnell,et al.  The homeodomain protein HOXB13 regulates the cellular response to androgens. , 2009, Molecular cell.

[26]  Christian Gieger,et al.  Correlation between Genetic and Geographic Structure in Europe , 2008, Current Biology.

[27]  R. Houlston,et al.  A systematic review and meta‐analysis of familial prostate cancer risk , 2003, BJU international.

[28]  H. Ostrer,et al.  Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma , 2003, Cancer.

[29]  Henrik Grönberg,et al.  Prostate cancer epidemiology , 2003, The Lancet.

[30]  A. Partin,et al.  Heredity and prostate cancer: A study of World War II veteran twins , 1997, The Prostate.

[31]  Z-Q Tao,et al.  Epidemiology of prostate cancer: current status. , 2015, European review for medical and pharmacological sciences.

[32]  Tao Zq,et al.  Epidemiology of prostate cancer: current status. , 2015 .

[33]  H. Grönberg,et al.  A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. , 2014, European urology.

[34]  J. Kirkpatrick.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, Journal of insurance medicine.

[35]  J. Sánchez Rodríguez,et al.  [Effect of complete androgen block before radical prostatectomy for cancer of the prostate]. , 1997, Archivos espanoles de urologia.

[36]  J. Oesterling,et al.  The effect of finasteride on prostate specific antigen: review of available data. , 1996, The Journal of urology.